Recombinant Human Osteoprotegerin (rHuOPG, O00300, 4982) CAS#: 108-08-1816; ChemWhat Code: 1404420

Official Full NameRecombinant Human Osteoprotegerin (rHuOPG)
SquenceSquence of Recombinant Human Osteoprotegerin
Amino Acid SequenceETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK
SynonymsTNFRSF11B, Osteoclastogenesis Inhibitory Factor, Tumor Necrosis Factor Receptor Superfamily Member 11B
Accession NumberO00300
GeneID4982
SummaryOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. OPG is a 401 a.a. basic glycoprotein which comprises 7 structural domains. It is either a 60 kDa monomer or a 120 kDa dimer linked by disulfide bridges. OPG acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro and may also play a role in preventing arterial calcification. OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Mature human OPG shares 86 %, 87 %, 92 %, 92 % and 88 % amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively.
SourceEscherichia coli.
Molecular WeightApproximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 173 amino acids.
Biological ActivityFully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL).
AppearanceSterile filtered white lyophilized (freeze-dried) powder.
FormulationLyophilized from a 0.2 um filtered concentrated solution in 20 mM PB,150 mM NaCl, pH 6.0.
EndotoxinLess than 1 EU/ug of rHuOPG as determined by LAL method.
ReconstitutionWe recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
References
SDS-PAGESDS-PAGE of Recombinant Human Osteoprotegerin
Safety Data Sheet (SDS) DownloadClick to download
Technical Data Sheet (TDS) DownloadClick to download

Buy Reagent

ChemWhat 140442010ug/100ug/500ug (> 95 % by SDS-PAGE and HPLC)
No reagent supplier?Send quick inquiry to ChemWhat
Want to be listed here as a reagent supplier? (Paid service)Click here to contact ChemWhat

Approved Manufacturers

Want to be listed as an approved manufacturer (Requires approvement)?Please download and fill out this form and send back to [email protected]

Contact Us for Other Help

Contact us for other information or servicesClick here to contact ChemWhat